Box plots of the three-dimensional displacement variations and the COR. by Yifei Li (198040)

Subjects:

Comparison between simulation tests and bench tests. by Yifei Li (198040)

Subjects:

Diagram of displacement variation. by Yifei Li (198040)

Subjects:

Scheme and results of orthogonal test. by Yifei Li (198040)

Subjects:

Comparison between simulation tests and bench tests. by Yifei Li (198040)

Subjects:

The millet mode. by Yifei Li (198040)

Subjects:

Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque count. by Francesca Catto (21253435)

“…Each map represents a 3-dimensional view of statistically affected voxels (p < 0.05), where the red scale indicates a decrease in plaque count, and the cyan scale represents an increase. …”

Technical properties of tested UASs. by Marc Roswag (20598443)

“…Our results support this hypothesis, because multicopter flights have a highly significant negative impact on bat activity levels with a medium effect size, particularly for the Myotini (<i>P</i> < 0.001, <i>d</i>_<i>m</i> = 0.54) and Nyctaloid group (<i>P</i> < 0.001, <i>d</i>_<i>n</i> = 0.55) and a small effect size for the Pipistrelloid group (<i>P</i> < 0.001, <i>d</i>_<i>p</i> = 0.36). …”

Sound stress exposure prolonged the period of decreased withdrawal threshold after complete Freund’s adjuvant (CFA) injection. by Satoka Kasai (3861115)

“…(B) 50% withdrawal threshold in CFA-treated mice exposed to sound stress. They showed a significant decrease in 50% withdrawal threshold on day 7 after CFA injection, and CFA-treated mice exposed to sound stress showed a significant decrease in 50% withdrawal threshold during days 7–21 after CFA injection (CFA, on day 7, ****<i>P</i> < 0.001 vs day 0, on day 10, ***<i>P</i> < 0.001 vs day0; CFA + stress, day 7, 10, 14, and 21, ****<i>P</i> < 0.0001 vs day 0, Dunnett’s test). …”

Summary of Biomarker Expression in Benign Samples. The STT and LTT groups exhibit significant changes in biomarker expression compared to the nontreatment group, measured on a two-... by Jinho Lee (587173)

Subjects:

(A) Cardiovascular Disease and (B) type-2 Diabetes Mellitus, and (C) chronic kidney disease- related Age-Adjusted Mortality Rates per 100,000 in Adults in the United States, 1999 t... by Aman Goyal (19231397)

Subjects:

Annual incidence of insomnia disorder (ICD-CODE: G47) Bar: rate of insomnia disorder relative to all patients; Line: average number of outpatient visits for patients with insomnia... by Mingee Choi (15250732)

Subjects: “…treatment initiation decreased…”

Distribution of non-pharmacological treatment related to insomnia disorder (2002–2019). by Mingee Choi (15250732)

Subjects: “…treatment initiation decreased…”

Detailed treatment status of patients who did not receive non-pharmacological treatment at first diagnosis but received it later. by Mingee Choi (15250732)

Subjects: “…treatment initiation decreased…”

General information of patient who diagnosis insomnia disorder (N = 518,119). by Mingee Choi (15250732)

Subjects: “…treatment initiation decreased…”

Detailed treatment status of people who received non- pharmacological treatment at first diagnosis. by Mingee Choi (15250732)

Subjects: “…treatment initiation decreased…”

Treatment at first diagnosis of insomnia disorder (%). by Mingee Choi (15250732)

Subjects: “…treatment initiation decreased…”

FBP primarily decreases the protein level of HMGB1 by promoting its lysosomal degradation upon viral infection. by Penghui Hu (695020)

Decreased synthesis of VCAM-1, tubulin and dynein proteins in the heart of mice stimulated with EVs (green) or ICs (blue). by Alberto Cornet-Gomez (10676133)

“…The values represent the mean ± SEM, with significance set at p < 0.05 (*).…”

Cells lacking Cbf11 and/or Mga2 display nutrient-responsive decrease in lipid droplet (LD) content. by Anna Marešová (14375187)